The supply chain for autologous CAR-T therapies has been a focus of improvement since early trials, especially for the transport of cells. Significant investments have aimed to make the supply chain more predictable and reliable.

While outsourcing the supply chain to a single logistics supplier is now more feasible, active management of the supply chain remains crucial for maintaining quality and efficiency. Managing this task internally may lead to inefficiencies, especially when compared to using partners experienced in onboarding centers for multiple clients.

Watch this webinar for insights from a panel of industry experts who will discuss these developments and how the industry can continue refining its process. They will review the successes and challenges of both in-house and outsourced models based on their extensive experiences, compare various approaches to building a collection center network, and consider potential inefficiencies when approaching the task individually compared to using a partner.

Watch this webinar to:

• Gain insights into the current state of the industry regarding outsourcing versus insourcing collection center onboarding and operations
• Explore the coordination of cell therapy logistics to support autologous cell and gene therapies
• Understand the financial, timing, and control challenges associated with each approach
• Discover the basic framework for evaluating whether or not outsourcing makes sense in their particular situation